COVID-19 reinfection’very rare’, not a matter of concern: ICMR DG

COVID-19 reinfection’very rare’, not a matter of concern: ICMR DG

Read Time:3 Minute, 0 Second

Reinfection was “very, very rare” with COVID-19, however it may occur as had been seen in a case in Hong Kong. (Express Photo by Amit Mehra)

Coronavirus reinfection is feasible though it’s a “very rare” prevalence, ICMR DG Balram Bhargava mentioned on Tuesday and careworn that it’s not a matter of critical concern.

The remarks come amid suspected instances of COVID-19 reinfection being reported from overseas and from Indian states like Telangana, Karnataka, Gujarat, Punjab and Maharashtra.

Responding to a query on the difficulty, Bhargava advised a press convention that reinfection was “very, very rare” with COVID-19, however it may occur as had been seen in a case in Hong Kong.

“We have seen that someone gets measles and he is supposed to be protected all his life because he generates certain antibodies, but then we have seen reinfection occurring in measles.

“Similarly, we can have reinfection with COVID-19 as has been described by the case in Hong Kong and it is not a matter of serious concern,” Bhargava mentioned.

In an earlier press convention, he had mentioned that there was a have to learn the way lengthy the immunity lasts towards the an infection.

Also Read “Don’t Be Afraid”: Rahul Gandhi Jibe At PM After Centre’s China Statement In Parliament

On coronavirus vaccine improvement, the ICMR director normal mentioned three vaccines are at medical trial phases within the nation and two indigenously ones developed by Cadila and Bharat Biotech have accomplished phase-I trial. The outcomes are being analysed and so they have accomplished recruitment for the second part, he mentioned.

Serum Institute of India has accomplished part II-B3 trials of the Oxford COVID-19 vaccine candidate. There was a pause of seven days. They will begin the phase-III trial with 1,500 sufferers at 14 places in India after clearances, Bhargava mentioned.

The Drugs Controller General of India (DCGI) had directed Serum Institute of India to droop any new recruitment within the phase-II and III medical trial of the Oxford COVID-19 vaccine candidate until additional orders within the backdrop of pharma large AstraZeneca pausing the medical trials in different nations.

Speaking in regards to the vaccine developed in Russia, the ICMR DG mentioned their first research of 76 sufferers has been printed within the journal Lancet, which is “showing good effectiveness and immune-antibody generation”. He mentioned Russia has not but accomplished Phase-III trial.

Dialogues are occurring between the High-Level Committee on Vaccines and the Russian diplomats in regards to the mechanisms for conducting Phase-III trial in India, he mentioned.

British-Swedish biopharmaceutical large AstraZeneca and the University of Oxford had on Saturday mentioned that medical trials for his or her coronavirus vaccine have resumed within the United Kingdom after Medicines and Healthcare merchandise Regulatory Agency (MHRA) confirmed that the trials had been secure.

The human trials resumed days after a pause had been introduced within the trials after an adversarial response in a single of the individuals.

Addressing a question on the nationwide sero-survey, Bhargava mentioned the survey, which was performed in April-May and is being repeated after three months, has been accomplished in 68 out of 70 districts. After evaluation of the outcomes by this month finish, the 2 research could be in contrast, he mentioned.

The senior official added that the sero-survey additionally brings out an infection fatality charge, which was discovered to be between 0.5-0.6 within the final nationwide sero-survey, which was a lot under than in lots of different nations.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleppy
Sleppy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Leave a Reply

Your email address will not be published. Required fields are marked *